In this episode, Joe Moore interviews Christopher Koddermann: Co-Founder and Chair of the Board of Directors of the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI), a group pursuing the rescheduling of psilocybin under the 1971 Convention on Psychotropic Substances – which has made attempts at academic research and clinical trials very time-consuming, overly complicated, and expensive. He discusses patents, IP, and “Psychedelics 2.0,” where companies are patenting new molecules, using IP to create investment interest, and patent-hopping. He also talks about market exclusivity and patents; ketamine, esketamine, and the case of China attempting to schedule ketamine; Ken Kesey; consumer preferences around natural products vs. synthetic; and the entourage effect and baeocystin, a compound present in many mushrooms.
The post PT347 – Christopher Koddermann – Rescheduling Psilocybin, Patents and IP, and The Entourage Effect appeared first on Psychedelics Today.
